Gelişimsel farmakoloji: Çocuklar küçük erişkinler değildir

Çocuklar erişkinlerden çok farklıdır. Büyüme ve gelişme hayatın ilk birkaç yılı boyunca çok hızlıdır ve matürasyon orta ve geç çocukluk çağı boyunca yavaş bir hızla devam eder. Vücut kompozisyonunda, vücut oranında, karaciğer ve böbreklerin kitlesinde gelişimsel değişimler farklı yaşlarda ilaçların farmakokinetik özelliklerini etkilemek-tedir. Bu nedenle çocukluk çağında yer alan değişiklik-lerin ilişkisini anlamak önemlidir. Çocuk popülasyonunda ilaçların kullanımı için ilaçların farmakokinetik ve farma-kodinamik davranışını anlamak optimal ve rasyonel ilaç tedavisi için gereklidir. Genel farmakokinetik prensiplerin uygulanması uygun çocuk dozuna karar verilmesinde esastır. Çocuk hastalarda ilaçların uygun kullanımı ço-cuklar için güvenli ve etkili dozajın belirlenmesini gerek-tirmektedir. Gelişimsel, genetik ve diğer klinik özelliklerle çocuklar ve erişkinler arasındaki belirleyici faktörlerin belirlenmesi çocuk hastaların tedavisinin en uygun hale gelmesine izin verecektir.

Developmental Pharmacology: Children are not small adults

Children are quite different from adults. Growth and development are most rapid during the first severel years of life and maturation continious at a slower pace throughout middle and later childhood. Developmental changes in body composition, body proportions, mass of the liver and kidneys affect pharmacokinetic characte-ristics of drugs at differet ages. It is therefore important to understand the relative changes that take place in childhood. Understanding the pharmacokinetic and pharmacodynamic behaviour of a drug in the pediatric population for its use is needed for optimal and rational drug therapy. Aplication of general pharmacokinetic principles is essential to determine appropriate pediatric dosage. Appropriate use of drugs in pediatric patients requires determining the safe and effective dosage for children. Defining the determinants between children and adults variability by developmental, genetic and other clinic characteristics allows optimization of treatment for pediatric patient.

PDF

___

1.
DH Andersen, WA Blanc, DN Crozier, WA Silverman. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens, Pediatrics 1956;18: 614–24. 2.
JM Sutherland. Fatal cardiovascular collapse of infants receiving large amount of chloramphenicol. Am J Dis Child 1959;97: 761–7. 3.
Weiss CF, Glazko A, Weston JK. Chloramphenicol in the newborn infant. N Engl J Med 1960;262: 787-94. 4.
Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for drug Investigation in Children. BMJ 2000;320: 79-82. 5.
Efron D, Hiscock H, Sewell JR, Cranswick NE, Vance AL, TYL Y. Prescribing of psychotropic medications for children by Australian paediatricians and child psychiatrists. Pediatrics 2003;111: 372-5. 6.
Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: From neonates to adolescents. Adv Drug Deliv Rev 2006;58: 4-14. 7.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349: 1157-67. 8.
The Bantam Medical Dictionary (2nd edition), New York: Bantam Books 1996; 313. 9.
Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000;106: 128-38. 10.
Alcorn J, McNamara, PJ. Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants: Part I. Clin Pharmacokinet 2002;41: 959-98. 11.
Atkinson AJ. Introduction to Clinical Pharmacology. In: Atkinsin AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP editors. Principles of Clinical Pharmacology. New York: Academic Press 2001; 1-6. 12.
Huang NN, High RH. Comparision of serum levels following the administration of oral and parenteral preportions of penicillin to infants and children of various age groups. J Pediatr 1953;42: 657-68. 13.
Silverio J, Poole JW. Serum concentrations of ampicilin in newborn infants after oral administration. Pediatrics 1973;51: 578-80. 14.
Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. Ped Rev 1998;19: 423-8. 15.
Gupta M, Brans YW. Gastric retention in neonates. Pediatrics 1978; 62: 26-9. 16.
Ittmann PI, Amarnath RA, Berseth CL. Maturation of antroduodenal motor activity in preterm and term infants. Dig Dis Sci 1992;37: 14-9. 17.
Berseth CL. Gestational evolution of small intestine motility in preterm and term infants. J Pediatr 1989;115: 646-51. 18.
Weaver LT, Austin S, Cole TJ. Small intestinal length: a factor essential for gut adaptation. Gut 1991;32: 1321-3. 19.
Linday L, Dobkin JF, Wang TC, Butler VP Jr, Saha JR, Lindenbaum J. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics 1987;79: 544-8. 20.
Johnson TN, Tanner MS, Christopher J, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a pediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001;51: 451-60. 21.
Stahlberg MR, Hiatene E, Maki M. Mucosal biotransformation rates in the small intestine of children. Gut 1988;29: 1058-63. 22.
Gibbs JB, Liacouras CA, Baldassano RN, Slattery JT. Up regulation of glutathiones-transferase activity in enterocytes of young children. Drug Metab Dispos 1999;27: 1466-69. 23.
Yaffe SJ, Juchau MR. Perinatal pharmacology. Annu REV Pharmacol 1974;14: 219-38. 24.
Alcorn J, McNamara PC. Pharmacokinetics in the newborn. Adv Drug Del REV 2003;55: 667-86. 25.
McClean P, Weaver LT. Ontogeny of human pancreatic exocrine function. Arch Dis Child 1993;68: 62-5. 26.
Rutter N. Percutaneous drug absorption in the newborn: hazards and uses. Clin Perinatol 1987;14: 911-30. 27.
Okah FA, Wickett RR, Pickens WL, Hoath SB. Surface electrical capacitance as a noninvasive bedside measure of epidermal barier maturation in the newborn infant. Pediatrics 1995;96: 688-92. 28.
Fluhr JW, Pfisterer S, Gloor M. Direct comparison of skin physiology in children and adults with bioengineering methods. Pediatr Dermatol 2000;17: 436-9. 29.
Amato M, Huppi P, Isenschmid M, Schneider H. Developmental aspects of percutaneous caffeine absorption in premature infants. Am J Perinatol 1992;9: 431-4. 30.
West DP, Worobec S, Solomon LM. Pharmacology and toxicology of infant skin. J Invest Dermatol 1981;76: 147-50. 31.
Greenblatt DJ, Koch-Weser J. Intramuscular injection of drugs. N Engl J Med 1976;295: 542-6. 32.
Kafetzis DA, Sinaniotis CA, Papadatos CJ, Kosmidis J. Pharmaco-kinetics of amikacin in infants and pre-school children. Acta Paediatr Scand 1979;68: 419-22. 33.
Sheng KT, Huang NN, Promadhattavedi V. Serum concentrations of cephalothin in infants and children and placental transmission of the antibiotic. Antimicrob Agents hemother 1964; 200-6. 34.
Schiller-Scotland CF, Hlawa R, Gebhart J. Experimental data for total deposition in the respiratory tract of children. Toxicol Lett 1994;72: 137-44. 35.
Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand 1983;305: 7-11. 36.
Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, Koren G. Back to basics: understanding drugs in children: pharmacokinetic maturation. Pediatr Rev 2005;26: 321-8. 37.
Siber GR, Echeverria P, Smith AL, Paisley JW, Smith DH. Pharma-cokinetics of gentamicin in children and adults. J Infect Dis 1975; 132: 637-51. 38.
Windorfer A, Kuenzer W, Urbanek R. The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding. Eur J Clin Pharmacol 1974;7: 227-31. 39.
Ehrnebo M, Agurell S, Jalling B, Boreus LO. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol 1971;3: 189-93. 40.
Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42: 59-98. 41.
Beneditti MS, Baltes EL. Drug metabolism and disposition in children. Fund Clin Pharmacol 2003;17: 281-99. 42.
Niederhauser VP. Prescribing for children: issues in pediatric pharmacology. Nurse Pract 1997;22: 16-8. 43.
Gibaldi M. Drug disposition- distrubition. In: Biopharmaceutics and clinical phramapharmco kinetics. 3rd edition. Lea and Febiger, Philedelphia, 1984; 168-180. 44.
Mac Namara PJ, Alcorn J. Protein binding predictions in infants. AAPS Pharma Sci 2002;4: 1-8. 45.
Gorodischer R, Jusco WJ, Yaffe SJ. Tissue and erythrocytes distrubition of digoxin in infants. Clin Pharmacol Ther 1976;19: 256-63. 46.
Kearin M, Kelly JG, O’Malley K. Digoxin ‘receptors’ in neonates: An explanation of less sensitivitiy to digoxin in adults. Clin Pharmacol Therap 1980;28: 346-49. 47.
Young WS, Lietman PS. Chloramphenicol glucuronyl transferase: assay, ontogeny and inducibility. J Pharmacol Exp Ther 1978;204: 203-11. 48.
Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002;300: 355-60. 49.
McCarver DG, Hines RN. The ontogeny of human drug metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002;300: 361-6. 50.
Crestil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam 1998;15: 45-51. 51.
Kinirons MT, O’Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999;66: 224-31. 52.
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37: 485-505. 53.
Pynnönen S, Sillanpäa M, Frey H, Iisalo E. Carbamazepine and its 10,11-epoxide in children and adults with epilepsy. Eur J Clin Pharmacol 1977;11: 129-33. 54.
Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11- epoxide formation. Biochem Pharmacol 1994;47: 1969-79. 55.
Riva R, Contin M, Albani F, Perucca E, Procaccianti G, Baruzzi A. Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults: influence of age and phenobarbitone co-medication. Clin Pharmacokinet 1985;10: 524-31. 56.
Bajpai M, Roskos LK, Shen DD, Levy RH. Rules of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24: 1401-3. infants. J Clin Pharmacol 1998;38:1089-95. 57.
Loughnan PM, Greenwald A, Purton WW, Aranda JV, Watters G, Neims AH. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. Arch Dis Child 1977;52: 302-9. 58.
Aranda JV, Collinge JM, Zinman R, Watters G. Maturation of caffeine elimination in infancy. Arch Dis Child 1979;54: 946-9. 59.
Kraus DM, Fischer JH, Reitz SJ, Kecskes SA, Yeh TF, McCulloch KM, et al. Alterations in theophylline metabolism during the first year of life. Clin Pharmacol Ther 1993;54: 351-9. 60.
Milavetz G, Vaughan LM, Weinberger MM, Hendeles L. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. J Pediatr 1986;109: 351-4. 61.
May DG. Genetic differences in drug disposition. J Clin Pharmacol 1994;34: 881-97. 62.
Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976;19: 284-94. 63.
Barrett DA, Barker DP, Rutter N, Pawula M, Shaw PN. Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Br J Clin Pharmacol 1996;41: 531-7. 64.
Scott CS, Riggs KW, Ling EW, Fitzgerald CE, Hill ML, Grunau RV, et al. Morphine pharmacokinetics and pain assessment in premature newborns. J Pediatr 1999;135: 423-9. 65.
Shargel L, Yu ABC. Drug clearance. In: İntroduction to pharmaco-kinetics: Applied Biopharmaceutics and Phramapharmcokinetics 3rd edition. Norwalk: Appleton & Lange. 1993; p: 265-92. 66.
Robillard JE, Guillery EN, Petershack JA. Renal function during fetal life. In: Barratt TM, Avner ED, Harmon WE, eds. Pediatric nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins 1999;p: 21-37. 67.
Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 1978;92: 705-12. 68.
Brown RD, Campoli-Richards M. Antimicrobial therapy in neonates, infants and children. Clin Pharmacokinet 1989;17: 105-15. 69.
Blowey DL, Ben-David S, Koren G. Interactions of drugs with a developing kidney. Pediatr Clin North Am 1995;42: 1415-31. 70.
Jacobs RF, Kearns GL, Brown AL, Trang HM, Kluza RB. Renal clearence of imipenem in children. Eur J Microbiol 1984;3: 471-4. 71.
Gibaldi M. Drug disposition-elimination. In: Biopharmaceutics and clinical phramapharmcokinetics. 3rd edition. Philedelphia: Lea and Febiger. 1984; 181-205. 72.
Jones DP, Chesney RW. Development of tubuler function. Clin Perinatol 1992;19: 33-57. 73.
Hua MJ, Kun HY, Jie JS, Yun NZ, De WQ, et al. Urinary microalbumin and retinol-binding protein assay for verifing Children’s nefron development and maturation. Clin Chim Acta 1997;264: 127-32. 74.
Drug formulary and data summary. In: Principles of Medical Pharmacology 4th edition. Roschlau WHE (executive editor). Toronto: Universty of Toronto Pres 1985; 888. 75.
Szefler SJ, Wynn RJ, Clarke DF, Buckwald S, Shen D, et al. Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr 1980;97: 312-15. 76.
Shargel L, Yu ABC. Relationship between pharmacokinetics and pharmacological response. In: İntroduction to pharmacokinetics: Applied Biopharmaceutics and Phramapharmcokinetics 3rd edition. Norwalk: Appleton & Lange 1993; 465-91. 77.
Endrenyi L. Dose-response relationship. In: Kalant H, Roschlau WHE, Sellers EM editors. Principles of Medical Pharmacology 4th edition. Toronto: Universty of Toronto Pres 1985; 91-8. 78.
Gibaldi M. Drug disposition-elimination. In: Biopharmaceutics and Clinical Phramapharmco kinetics. 3rd edition. Philedelphia: Lea and Febiger. 1984; 156-67. 79.
Stephenson T. How children’s responses to drugs differ from adults. Br J Clin Pharmacol 2005;59: 670-73. 80.
Fox E, Balis FM. Drug therapy in neonates and pediatric patients. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Marley SP editors. Principles of clinical pharmacology. New York: Academic Pres 2001; 293-305. 81.
Blumer JL. Clinical pharmacology of midazolam in infants and children. Clin Pharmacokinet 1998;35: 37-47. 82.
Tolia V, Brennan S, Aravind MK, Kauffman RE. Pharmacokinetic and pharmacodynamic study of midazolam in children during eosaphagogastroduadenoscopy. J Pediatr 1991;119: 467-71.